Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: S1CD9D4AED0AEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Understanding

The DelveInsight Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology report gives a thorough understanding of the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the US, Europe, and Japan. The report covers the detailed information of the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Perspective by DelveInsight

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Detailed Epidemiology Segmentation

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology covered in the report provides historical as well as forecasted Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Report and Model provide an overview of the global trends of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
• The report provides the segmentation of the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology

Report Highlights

• 11-year Forecast of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
• Cases of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) by Mutation Types
• Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)?
• What are the key findings pertaining to the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)?
• What are the currently available treatments of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)?

Reasons to buy

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market
• Quantify patient populations in the global Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) therapeutics in each of the markets covered
• Understand the magnitude of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) population by its epidemiology
• The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

3. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Treatment and Management
6.2. Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in 7MM (2019-2032)
Table 2: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in the United States (2019-2032)
Table 4: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Germany (2019-2032)
Table 6: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in France (2019-2032)
Table 8: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Italy (2019-2032)
Table 10: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Spain (2019-2032)
Table 12: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Japan (2019-2032)
Table 16: Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in 7MM (2019-2032)
Figure 2 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in the United States (2019-2032)
Figure 4 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Germany (2019-2032)
Figure 6 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in France (2019-2032)
Figure 8 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Italy (2019-2032)
Figure 10 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Spain (2019-2032)
Figure 12 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Epidemiology in Japan (2019-2032)
Figure 16 Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report